Rapamycin Mouth Ulcers: The Most Common Side Effect

In cancer patients on daily mTOR inhibitors at the strengths used there, mouth ulcers affect a large proportion — in some trials the majority — and are the most common reason for interrupting treatment. Longevity use is different: intermittent rather than daily, and at a fraction of the exposure. The rate is correspondingly lower, but it is not low.

The best data on longevity users come from a 2023 survey of several hundred people taking rapamycin off-label, published by researchers at the University of Washington: mouth sores were the most commonly reported side effect, noted by a substantial minority, alongside a smaller number reporting stomach upset or acne-like skin changes. The first randomized, placebo-controlled trial of intermittent rapamycin in healthy adults, published in 2025, found no significant increase in adverse events overall over a year, which is reassuring on serious harms — but mouth ulcers are a nuisance rather than a serious harm and were reported in that trial too.

The pattern most people describe: one or two ulcers in the first month, sometimes recurring around the day of the weekly tablet, then fewer and milder over the following months as the tissue adapts. A minority get none. A smaller minority get them persistently.

Mostly, that the drug is doing what it does. Mouth ulcers on rapamycin are not a sign of infection, of immune failure, or of a problem with the liver or blood count — the things the monitoring labs on the main page are watching for. They are a local effect on a fast-growing tissue and, on their own, they do not change the labs.

Where they do carry information is in their severity. Frequent, large or multiple ulcers, or ulcers that prevent eating or drinking normally, are a sign that the exposure is higher than the tissue can tolerate — which may be the schedule, or may be an interaction that is raising the drug's blood level. The main page is emphatic that interactions are a bigger issue with rapamycin than people expect, and severe stomatitis is one of the ways an interaction announces itself. It is a reason to tell your clinician, not to push through.

The measures with evidence come from oncology, where the problem is worse and has been studied. A steroid mouth rinse used preventively substantially reduced the incidence and severity of mTOR-inhibitor ulcers in a large cancer trial, and is the standard approach there; it is a prescription and a decision for your clinician, not something to improvise. Beyond that, the practical measures are the ones for any aphthous ulcer: an alcohol-free mouthwash, avoiding acidic, spicy and sharp-edged food while an ulcer is active, a soft toothbrush, and over-the-counter numbing gels for pain. Some people find that taking the tablet with food rather than on an empty stomach reduces the mouth effect; the evidence for that is anecdotal.

What we do not set out here is any change to how the drug itself is taken. That is a clinical decision made with your prescriber, informed by the severity of the ulcers, the labs, and the interaction check — and it is the conversation to have rather than adjusting on your own.

Rarely, but it happens. A person whose ulcers are persistent, painful and interfering with eating despite the measures above, whose schedule has been reviewed, and whose interaction check is clean, has a drug they do not tolerate. That is a legitimate reason to stop, and it is a better reason than most — a treatment whose benefit is probabilistic and long-term does not justify a daily harm that is certain and immediate. The main page frames the whole decision that way, and this is one of the places it applies.